RE:RE:RE:RE:RE:Lumeda and NSCLC Hey , if you save late stage cancer patients with a high rate of survival you can bet your bottom dollar that early stage patients will be questioning their oncologist about PDT/PDC therapies . Buffalo , a stone throw away from TO , TLT should of been there with a PH1b . Here I go again crying over spilled milk . I was told I was too early asking for a partnership/licensing deal . Too early for NASDAQ but wait we have the best science . GLTA JOJO Member of the bought too soon club
Quattro74 wrote: enriquesuave wrote: They are going to be using PDT at the same time as surgery to target tumour margins. I believe that we will try to replace surgery altogether here, but both indications may be in play for Rutherin? Time will tell.
Interesting Guys. I think that eventually Rutherin will be used, yes. Also, replacing surgery eventually. At first though TLTs ACT for late stage/out of options patients. Should help TLT get their foot in the door. Imagine those patients with difficult or low % survival surgeries. Then TLT's solution starts saving them.....